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ABSTRACT
Introduction Approximately 40% of the 55 000 women 
diagnosed with breast cancer each year in the UK undergo 
mastectomy because they are considered unsuitable for 
standard breast- conserving surgery (BCS) due to tumour 
size or multiple tumour foci. Mastectomy can significantly 
impact women’s quality of life, and only one in four women 
currently undergo immediate breast reconstruction (IBR).
Level 2 oncoplastic breast- conserving surgery (OPBCS) 
combines removing the cancer with a range of plastic 
surgical volume replacement (eg, local perforator flaps) 
and volume displacement techniques (eg, therapeutic 
mammaplasty) that can extend the role of BCS and may 
allow some women not suitable for standard BCS to 
avoid mastectomy. High- quality research to determine 
whether OPBCS offers a safe and effective alternative to 
mastectomy±IBR is currently lacking. Preliminary work 
is needed to ensure a future large- scale study is feasible 
and well designed and addresses questions important to 
patients and the National Health Service.
Methods and analysis Mixed methods will be used to 
inform feasibility and design of a future large- scale study 
comparing the clinical effectiveness and cost- effectiveness 
of OPBCS and mastectomy±IBR. It will have four parts: 
(1) a National Practice Questionnaire to determine 
current practice and provision of oncoplastic breast and 
reconstructive surgery in the UK; (2) a pilot multicentre 
prospective cohort study to explore the proportion 
of patients choosing OPBCS versus mastectomy, the 
proportion in OPBCS is successful and clinical and 
patient- reported outcomes of different techniques at 3 
and 12 months postsurgery; (3) a qualitative interview 
study to explore patients’ attitudes to different procedures, 
rationale for decision- making and perceptions of 
outcomes; and (4) design of the future study.
All centres offering OPBCS and mastectomy in the UK 
will be invited to participate. Recruitment is planned to 
commence winter 2020 and continue for 12 months.
Strengths and limitations of this study
 ► This mixed- method study will determine wheth-
er it is possible to undertake a large prospective 
cohort study directly comparing the clinical ef-
fectiveness and cost- effectiveness of oncoplastic 
breast- conserving surgery (OPBCS) and mastecto-
my with or without breast reconstruction in patients 
considered suitable for both procedures.
 ► It will determine whether the BREAST- Q core breast 
cancer modules are an appropriate and meaningful 
patient- reported outcome measure for use in a fu-
ture comparative study.
 ► Qualitative interviews will explore patients’ atti-
tudes to different procedures, rationale for decision- 
making, and perception of outcomes providing the 
opportunity to improve informed consent in this 
group.
 ► Suitability for OPBCS will be assessed by individual 
surgeons or teams. It is multifactorial with subjective 
elements and is likely to vary between individuals 
and centres.
 ► Patients will only be followed up for 12 months, and 
the effects of radiotherapy and any revisional sur-
gery are likely to occur at a later time point.
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Ethics and dissemination The study has ethical approval from the Wales 
Research Ethics Committee 6 National Research Ethics Service (REC 
Ref 20/WA/0225). Results will be presented at national and international 
meetings and published in peer- reviewed journals. We will work with 
patients to develop lay summaries and share these through patient groups 
and breast cancer charities.
Trial registration number ISRCTN18238549.
INTRODUCTION
Despite improvements in treatment, approximately 40%1 
of the 55 000 women2 diagnosed with breast cancer every 
year in the UK undergo mastectomy (Mx) as they are 
considered unsuitable for standard breast- conserving 
surgery (BCS) due to tumour size or multiple tumour 
foci. Mx may dramatically impact women’s quality of 
life,3 4 and although national guidelines5 recommend 
that immediate breast reconstruction (IBR) should be 
routinely offered in this group, only a quarter of women 
currently receive reconstruction6 due to a combination 
of patient- related and treatment- related factors.7 While 
some women may chose Mx with or without reconstruc-
tion to reduce their risk of recurrence or to avoid the 
need for radiotherapy, especially in the North American 
setting,8 9 BCS is associated with greater patient satis-
faction and improved quality of life,4 and many women 
would chose this approach if possible.
Level 2 oncoplastic breast- conserving surgery 
(OPBCS) describes a range of volume replacement 
and volume displacement techniques that may extend 
the boundaries of breast conservation and allow some 
women not suitable for standard BCS to avoid Mx. 
Volume displacement techniques, often termed ther-
apeutic mammaplasty (TM), combine removing the 
cancer (wide local excision) with breast reduction and 
mastopexy techniques to reshape the remaining breast 
tissue.10 11 These techniques allow resection of large or 
multifocal cancers in patients with medium/large or 
ptotic breasts without compromising cosmetic or onco-
logical outcomes.12–14 Volume replacement or partial 
breast reconstruction techniques involve using local 
flaps to fill the defect left following a wide local exci-
sion.15 These flaps have particular value in patients with 
small or medium breasts with little ptosis and may offer 
good cosmetic outcomes without the need for contralat-
eral symmetrisation.16 Latissimus dorsi miniflaps have 
been most frequently described, but more recently, 
muscle- preserving local perforator flaps (LPFs) such as 
those based on the intercostal artery perforators (ICAPs) 
(lateral and anterior ICAP flaps), thoracodorsal artery 
perforator and lateral thoracic artery perforator have 
gained in popularity17 and do not compromise shoulder 
function or future reconstructive options.18
There is, however, limited high- quality comparative 
evidence to support the benefits of OPBCS as an alter-
native to Mx with or without IBR in women unsuitable 
for standard BCS. Recent combined analysis of 2540 
patients who underwent Mx with or without IBR in the 
iBRA-2 (immediate breast reconstruction and adjuvant 
therapy audit)Study19 and a subgroup of 376 patients who 
underwent TM to avoid Mx in the TeaM (Therapeutic 
Mammaplasty) Study20 suggests that although patients in 
the TM group were ‘higher risk’ (ie, older, higher body 
mass index and more likely to be smokers) than those 
undergoing IBR, rates of major complications requiring 
readmission or reoperation were significantly lower in 
the TM group (2.1% TM vs 14.8% implant- based recon-
struction; 16.7% free- flap reconstruction).21 The tumour 
characteristics were similar in all groups (median whole 
tumour size 30 mm and multifocality 31.3%), and TM 
allowed successful breast conservation in almost 90% of 
cases.21 Single- centre case series suggests that patients 
undergoing TM may report better quality of life than 
those undergoing Mx and IBR,22 23 and there is emerging 
evidence to suggest that TM may be a cost- effective alter-
native to Mx and immediate implant- based24 and free- flap 
reconstruction25 in a North American setting.
While these results are promising, there remains a 
need for high- quality research to establish the benefits 
of OPBCS as a safe and effective alternative to Mx±IBR. 
Randomised trials are ideally needed, but randomised 
controlled trials in this context have not been possible due 
to strong patient and surgeon preferences.26 27 A large- 
scale multicentre prospective cohort study is therefore 
required to compare the clinical and patient- reported 
outcomes (PROs) of OPBCS and Mx±IBR and to evaluate 
the cost- effectiveness of the approach.
Before such a study can be planned, however, prelimi-
nary work is needed to determine whether a comparative 
study would be feasible, in particular to explore whether 
sufficient numbers of centres are offering patients OPBCS 
to avoid Mx; how many patients are offered OPBCS and 
in what circumstances; of those offered OPBCS, what 
proportion accepts or declines the procedure and why; 
and the rate of successful BCS. It is also important to estab-
lish whether existing outcome measures capture relevant 
core outcome domains and are appropriate for use across 
all patient groups. If not, refinement of existing tools will 
be needed prior to progression to the main study.
METHODS AND ANALYSIS
Primary aim
The overall aim of the ANTHEM Study is to use mixed 
methods to assess the feasibility of undertaking a large- 
scale multicentre prospective cohort study to compare 
the clinical effectiveness and cost- effectiveness of OPBCS 
as a safe and effective alternative to Mx±IBR and to deter-
mine the most appropriate outcome measures for use 
in the main study. The study will also explore women’s 
decision- making for particular surgical procedures, ratio-
nale for choice, and their perceptions of outcome.
Study design
The ANTHEM Feasibility Study will consist of four parts:
1. National Practice Questionnaire (NPQ)
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2. Pilot prospective cohort study
3. Qualitative interview study
4. Design of main study
Patient and public involvement
The protocol for the ANTHEM Study has been code-
veloped in collaboration with a patient representative 
and addresses a key research gap highlighted by patient 
contributors to the recent Association of Breast Surgery 
Gap Analysis.28 Patient representatives will sit on the study 
steering committee and comment on study documents 
including patient information sheets and topic guides for 
the qualitative interviews to ensure that all aspects of the 
study are patient focused and explore issues that patients’ 
value. During the study, we will also establish a patient 
group (6–10 women who have undergone a range of 
surgery for breast cancer including TM, LPF procedures, 
Mx and immediate or delayed reconstruction using 
different techniques) to advise on the design of a future 
main study.
Part 1: National Practice Questionnaire
The NPQ is a nested service evaluation that aims to deter-
mine the availability of different approaches to OPBCS 
(TM and LPFs) and breast reconstruction procedures 
nationally and understand current practice to inform a 
future study.
Specific objectives will include the following:
i. To establish the number of centres/surgeons per-
forming OPBCS (volume displacement and volume 
replacement techniques) to participate in the future 
study
ii. To determine the approximate numbers of OPBCS 
(TM/LPF) performed to avoid Mx at a centre level 
to inform the feasibility of a future comparative study
iii. To determine the indications/contraindications 
for OPBCS/IBR at the surgeon/centre level and 
patient/tumour/treatment factors influencing 
decision- making
iv. To explore patient pathways (neoadjuvant treat-
ments/symmetrisation/day case/follow- up) to in-
form study design
The NPQ will be developed by members of the 
steering group using REDCap29 data management soft-
ware and will explore current practice at participating 
centres. This will include the availability of oncoplastic 
breast- conserving (TM and LPFs) and reconstructive 
(implant- based and autologous) techniques locally; 
indications and contraindications for each technique; 
patient- related, tumour- related and treatment- related 
factors influencing decision- making; and information 
regarding patient pathways including the use of neoadju-
vant therapy, approaches to contralateral symmetrisation 
surgery, provision of day case versus inpatient procedures 
and timing of routine follow- up to inform future study 
design. The survey will be piloted with surgeons to estab-
lish face and content validity and acceptability prior to 
dissemination.
All breast and plastic surgical units performing breast 
cancer surgery in the UK will be invited to complete the 
NPQ via the professional associations (Association of 
Breast Surgery and British Association of Plastic, Recon-
structive & Aesthetic Surgeons (BAPRAS)), collaborative 
networks including the iBRA- NET group and the Recon-
structive Trials Network and social media with the aim of 
optimising the number of participating sites. One ques-
tionnaire will be completed per unit.
Simple summary statistics will be used to describe the 
provision and practice of oncoplastic and reconstructive 
surgery. Categorical data will be summarised using counts 
and percentages. Median, IQR and range will be used 
for continuous data. Free- response fields will be analysed 
using a thematic analysis approach.
Part 2: pilot prospective cohort study
The aim of the pilot cohort study is to determine the 
feasibility of identifying and recruiting patients offered 
different approaches to OPBCS to avoid Mx and to 
explore the utility of the BREAST- Q as an outcome 
measure for the main study.
Specific objectives will include the following:
i. To determine the number of patients offered OPBCS 
to avoid Mx, the relative numbers of volume displace-
ment and volume replacement procedures offered, 
the number of patients electing to undergo OPBCS, 
the success rates of OPBCS and the outcomes for pa-
tients in whom further surgery is needed
ii. To establish the clinical outcomes of TM/LPF/
Mx±IBR.
iii. To determine whether existing tools (breast cancer 
core domains of the BREAST- Q) are valid in the 
OPBCS population and whether these subscales are 
directly comparable across patient groups.
iv. To explore variability in BREAST- Q Breast Cancer 
Core Scales to inform sample size calculations for the 
main study
v. To explore the feasibility of collecting electronic 
PROs.
vi. To explore the feasibility of collecting multicentre 
resource- use data using a targeted approach for cost- 
effectiveness evaluation in the main study
Setting
All UK breast and plastic surgical centres currently 
performing oncoplastic techniques (therapeutic mammo-
plasty and chest wall perforator flaps) will be invited to 
participate in the study through research collaborative 
networks including the Association of Breast Surgery, 
BAPRAS, iBRA- NET group and the National Institute for 
Health Research Clinical Research Network.
Participants
Eligibility criteria
Inclusion criteria will be:
 ► All female patients 18 years and over
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 ► With invasive breast cancer or ductal carcinoma in situ 
not considered suitable for standard BCS or simple 
level 1 techniques
 ► Who are assessed by the breast cancer (and onco-
plastic, if applicable) multidisciplinary team (MDT) 
and the operating surgeon as being suitable candi-
dates for either OPBCS (either TM or LPF) as an 
alternative to an Mx with or without an IBR (using 
any technique)
 ► Offered both OPBCS and Mx options.
No restrictions will be placed on the size of the tumour 
as decisions on the suitability of a patient for simple BCS 
will be based on assessments of the size of the tumour 
relative to the overall size of the breast and its position 
within the breast rather than on explicit size criteria.
Exclusion criteria will be women not offered a choice 
of procedures, those offered OPBCS for reasons other 
than to avoid Mx (eg, quality of life if large breasted), 
women offered standard BCS or level 1 procedures only 
and women who have declined informed consent.
Participant identification and recruitment
Patients who are potentially suitable for either OPBCS 
or Mx will be identified from the breast cancer and/or 
oncoplastic MDT meetings. Potentially eligible patients 
will be assessed by their surgeon in clinic as per standard 
practice. If the operating surgeon considers the patient 
to be suitable for either OPBCS or Mx±IBR, they will be 
offered a choice of procedures. They will be invited to 
participate in the ANTHEM Study and given a patient 
information sheet. Patients will have the opportunity to 
discuss the study with a member of the local clinical or 
research team as per local practice, and if they elect to 
participate in the study, they will sign a study consent 
form.
Data collection and patient pathway
Baseline demographic and pre- operative assessment 
data will be collected. When the patient has made a deci-
sion regarding surgery, they will be asked to complete 
preoperative PRO measures (PROMs) (BREAST- Q/
EQ- 5D- 5L/ICECAP- A (ICEpop CAPability measure for 
Adults)) either electronically or on paper as per patient 
preference.
Patients will undergo surgery according to their prefer-
ence. Operative and oncological data will be collected. For 
patients undergoing OPBCS in whom adequate tumour 
resection as per local policy is not achieved, details of 
further procedures performed (re- excision of margins/
Mx±IBR/chemotherapy followed by further surgery) will 
be recorded. MDT decisions regarding adjuvant treat-
ment and postoperative complications at 3 months will be 
collected by clinical or case note review according to local 
practice. Complications and the need for further surgery 
will also be collected at 12 months. Patients will be asked 
to complete PROMs (BREAST- Q/EQ- 5D- 5L/ICECAP- A) 
at 3 and 12 months post- operatively.
The feasibility of collecting hospital resource- use data 
using case report forms (CRFs) developed from NPQ- 
patient pathway mapping will be assessed.
Outcome measures
Clinical outcomes
Complication rates at 3 and 12 months, in particular rates 
of readmission and reoperation for complications relating 
to breast surgery and time to adjuvant therapy defined 
as the number of days from the last cancer surgery to 
the first adjuvant treatment (first dose of chemotherapy 
or first fraction of radiotherapy), will be recorded and 
compared across surgical techniques. Standardised defi-
nitions of complications (listed in online supplemental 
appendix 1) will be used as per previous studies.19 20 For 
patients undergoing OPBCS, rates of successful breast 
conservation, defined as achievement of adequate resec-
tion margins as per local protocol, will be determined.
Patient-reported outcomes
It is anticipated that the primary outcome for the main 
study will be a PRO included in the reconstructive breast 
surgery core outcome set.30 It is vital that a PROM is 
chosen that is valid and reliable across all patient groups.
The BREAST- Q31 32 is a validated PROM that has been 
developed for use in a breast cancer population. It 
comprises preoperative and postoperative ‘core breast 
cancer modules’ in which the developers’ report can be 
used in patients undergoing breast conservation and Mx 
and IBR procedures, allowing different techniques to be 
effectively compared. Published evidence of compara-
bility, however, is lacking, and these modules have yet to 
be used in patients undergoing level 2 oncoplastic breast- 
conserving techniques (TM and LPF).
Key objectives of the feasibility phase are to determine 
whether the BREAST- Q subscales can be compared across 
different patient groups and whether they measure the 
constructs of interest within the study. Quantitative anal-
ysis will be used to explore acceptability (response rates) 
and construct validity (the extent to which the question-
naire actually measures what it claims to measure) of the 
BREAST- Q subscales. Face validity (applying a subjective 
assessment of whether or not a questionnaire measures 
what it is supposed to measure) will be assessed using 
qualitative interviews with study participants (part 3, 
patient interview study). If the BREAST- Q is shown to 
be useful in this group, variability in BREAST- Q Breast 
Cancer Core Scales will be explored to inform the sample 
size for the main study.
For economic evaluation in breast surgery, it is currently 
unclear whether the EQ- 5D- 5L (standard approach 
recommended by The National Institute for Health 
and Care Excellence (NICE)) or ICECAP- A (a broader 
measure of capabilities) is best suited to measure differ-
ences in outcome following breast surgery. The mixed- 
method approach used in this study will also provide 
data on the acceptability and validity (construct and face 
validity) of these latter two measures.
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The feasibility and acceptability of using centrally 
distributed electronic questionnaires will be assessed.
Exploring the feasibility of using targeted micro-costing to 
determine the relative costs of OPBCS versus Mx±IBR surgery
The feasibility of using recently described targeted micro- 
costing33 to determine the relative surgical costs of OPBCS 
and reconstructive procedures will be explored. Patient 
pathways for each surgical procedure will be mapped by the 
breast and plastic surgeons in the steering group informed 
by data from the NPQ.
The pathways will be used to identify resources 
required for each procedure including staff, equip-
ment, consumables, implants and length of patient 
stay. The lists will be reviewed to identify the main cost 
drivers for each technique and the key differences in 
resource use between techniques. These resources will 
be recorded in detail in the study CRFs. It is anticipated 
that different centres will have different processes for 
carrying out each procedure; therefore process maps 
and lists of resources will differ between centres. We will 
initially aim to focus on three centres for our targeted 
micro- costing feasibility study and determine whether it 
is possible to extend to all centres once the main cost 
drivers have been identified.
Targeted micro- costing will focus on the period between 
first preoperative visit and the end of the patient’s hospital 
stay. Additional data such as the number of outpatient visits 
will be collected from electronic notes/medical records.
Data analysis and sample size
The proportions of patients electing to undergo 
OPBCS/Mx±IBR will be summarised together with the 
proportion of patients in whom OPBCS is successful and 
those in whom further surgery is required, using simple 
summary statistics and compared between groups. 
PROMs will be scored according to the developers’ 
instructions and compared at 3 and 12 months across 
patient groups.
Individual BREAST- Q subscale scores will be compared 
across each of the study groups. Assessments of construct 
validity and responsiveness (ability of an instrument to 
detect change over time in the construct to be measured) 
of the BREAST- Q to changes in PROs from 3 months to 
12 months postsurgery will be explored to determine 
whether the BREAST- Q is a suitable instrument for use in 
the future large- scale study.
It is anticipated that patients in the OPBCS groups will 
be more satisfied with the outcome of their surgery at 
12 months than patients undergoing Mx±IBR. To allow 
the utility of the BREAST- Q for use in the main study to be 
determined, approximately 50 patients will be recruited 
in each group (OPBCS—volume replacement/OPBCS—
volume displacement/Mx only/Mx and implant recon-
struction/Mx and autologous reconstruction). It is 
anticipated that overall, approximately 250 patients will 
be recruited over a 12- month period.
Part 3. qualitative interview study
Semistructured qualitative interviews will be used to 
explore patients’ perceptions of choice within the study, 
rationale for decision- making, perception of outcomes 
and proposed outcome measures in more depth.
Specific objectives will be to explore the following:
i. Why patients chose different approaches and factors 
influencing this
ii. Patients’ perceptions of the outcomes of their surgery
iii. Whether proposed outcome measures address the is-
sues important to patients and appropriately reflect 
the key core outcome domains, in particular, satisfac-
tion with breasts, emotional and physical well- being 
and quality of life, and whether they are adequate or 
missing key concerns and the acceptability of the in-
dividual items
iv. Key aspects of future study design (outcome 
selection/timing)
Recruitment
All patients consenting to participate in the prospective 
cohort study will be invited to consent to be contacted 
regarding participation in the interview study at the time 
of study entry. Patients who consent to be contacted will 
be asked to provide contact details (e- mail, telephone or 
postal address) for this purpose.
If patients agree to be contacted about an interview, 
they will be invited in batches of 5–10 by their preferred 
contact method 3–12 months following surgery. Recruit-
ment to the interview study and data collection will be 
conducted and analysed concurrently and iteratively 
until data saturation (the point at which no new themes 
emerge) is considered to have been achieved.
Sampling
Consenting patients will be purposively sampled using a 
maximum- variation approach based on their procedure 
choice (OPBCS—volume replacement (LPF)/OPBCS—
volume displacement (TM)/Mx only/Mx with IBR/Mx 
with flaps), outcome (successful OPBCS/not) and partic-
ipating centre. Theoretical sampling will be used as the 
study progresses to include individuals whose views may 
enhance or disprove emerging themes.
Data collection
All interviews will be conducted by telephone by a qualita-
tive researcher using a semistructured topic guide devel-
oped by the study steering group based on a review of the 
literature and clinical expertise. Interviews will explore 
patients’ rationale for decision- making; perceptions of 
different options/outcomes; detailed views of the appro-
priateness, adequacy and acceptability of the proposed 
PROMs and views of the study design.
All interviews will be digitally audio- recorded using 
an encrypted recording device, transcribed verbatim 
by University of Bristol staff or a University of Bristol- 
approved transcription service, checked and anonymised 
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by the research team against the original recording to 
protect patient confidentiality.
Data analysis and sample size
Analysis of the interviews will be an ongoing and itera-
tive process commencing soon after data collection and 
informing further sampling. Transcripts will be system-
atically assigned codes using the qualitative data analysis 
package NVivo and analysed thematically34 using the 
constant comparison technique of grounded theory.35 
The themes identified from the interviews will be used 
to iteratively modify the interview topic guides as appro-
priate to explore emerging areas of interest in- depth. 
Data collection will continue until saturation is achieved 
and no new themes emerge from the data.
Part 4: design of main study
Parts 1–3 will inform the feasibility and design of a defin-
itive study, in particular the most appropriate primary 
outcome and tool by which this can be assessed.
ETHICS AND DISSEMINATION
Ethical approval for the study has been granted by the 
Wales Research Ethics Committee 6 (ref. number: 20/
WA/0225). Written informed consent will be obtained 
from patients for both the prospective cohort and inter-
view studies prior to study participation. Dissemination 
strategies will include presentations at scientific meeting 
presentations and publications in peer- reviewed journals. 
We will work with our patient and public involvement 
group to develop lay summaries to disseminate through 
patient groups and breast cancer charities. Findings will 
be fed back to the surgical community to promote engage-
ment and recruitment to a future large- scale multicentre 
prospective cohort study.
Study status
Recruitment is planned to commence winter 2020.
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